Download the Case Study
A Pivotal Phase III Registrational Trial for a New Class of Antibiotic for the Treatment of Uncomplicated UTIs
A Pivotal Phase III Registrational Trial for a New Class of Antibiotic for the Treatment of Uncomplicated UTIs
Strategic Approaches to Achieving Rapid Site Start-Up and FDA Approval in a Phase III UTI Study
In a newly released case study, the Medpace Women’s Health Leadership Team provide strategic approaches to achieving rapid site start-up and FDA approval in Urinary Tract Infections (UTI).
In this Phase III registrational trial for a new class of antibiotic for the treatment of uncomplicated Urinary Tract Infections (uUTIs), Medpace was able to surpass the site activation goal, complete enrollment ahead of schedule, and enable regulatory milestones.
Improving Healthcare for Women Across the Globe
Global Women’s Health CRO
At Medpace, we have a therapeutically aligned leadership team focused specifically on improving the execution and efficiency of Women’s Health clinical research in a number of diverse disciplines. When you partner with Medpace Women’s Health CRO, benefit from:
- Medical experts with extensive academic, clinical, and industry experience, in addition to strong relationships with relevant key opinion leaders, experienced sites, and investigators
- Therapeutic expertise across multiple areas relevant to Women’s Health, including board-certified physicians in Gynecology, Urogynecology , Oncology, Endocrinology, and Infectious Diseases
- A fully integrated and experienced clinical operations and medical team with experience in Phase I to IV Women’s Health clinical trials
Our goal at Medpace is ultimately to fill the many unmet clinical needs in Women’s Health and improve healthcare outcomes and quality of life for women across the globe.
